#1 Clinical Trials Search in Europe

Cyc140 Monohydrochloride Monohydrate

CYC140 Monohydrochloride Monohydrate is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors and lymphoma. This article provides an overview of the ongoing research, including the drug’s potential benefits, the types of cancers being targeted, and what patients can expect from participating in these trials.

Table of Contents

What is CYC140?

CYC140 is a new medication being studied for the treatment of advanced solid tumors and lymphoma. Its full name is CYC140 MONOHYDROCHLORIDE MONOHYDRATE, and it’s being developed by Cyclacel Limited[1]. This drug is currently in clinical trials, which means it’s being tested to see how well it works and how safe it is for patients.

How CYC140 Works

CYC140 is what’s known as an oral PLK1 inhibitor[1]. To understand what this means:

  • Oral: The medication is taken by mouth, usually in the form of a capsule.
  • PLK1: This stands for Polo-Like Kinase 1, which is a protein that plays a crucial role in cell division. In many types of cancer, there’s too much PLK1, which leads to uncontrolled cell growth.
  • Inhibitor: This means the drug works by blocking or reducing the activity of PLK1.

By inhibiting PLK1, CYC140 aims to slow down or stop the growth of cancer cells[1].

Medical Conditions Treated

CYC140 is being studied for the treatment of various types of advanced cancers, including[1]:

  • Metastatic colorectal cancer: Cancer of the colon or rectum that has spread to other parts of the body
  • Cholangiocarcinoma: Cancer of the bile ducts (both inside and outside the liver)
  • Hepatocellular carcinoma: The most common type of liver cancer
  • Non-small cell lung cancer: A common type of lung cancer
  • Small cell lung cancer: A less common, but often more aggressive type of lung cancer
  • Gallbladder carcinoma: Cancer of the gallbladder
  • Lymphoma: Cancer that begins in cells of the lymph system

Clinical Trial Overview

The clinical trial for CYC140 is a Phase 1/2 study, which means it combines two stages of testing[1]:

  1. Phase 1: This part of the study aims to determine the safest and most effective dose of CYC140. Researchers will be looking at how the drug is processed by the body (pharmacokinetics) and any side effects it may cause.
  2. Phase 2: This part of the study will evaluate how well CYC140 works in treating various types of advanced cancers. Researchers will measure the overall response rate, which means how many patients see their tumors shrink or disappear after treatment.

The study is described as “open-label,” which means both the patients and the doctors know which treatment is being given. It’s also “multicenter,” indicating that the study is being conducted at multiple hospitals or clinics[1].

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key points include[1]:

  • Be at least 18 years old
  • Have a confirmed diagnosis of advanced cancer that has either progressed after standard treatment or for which no standard treatment exists
  • Have at least one measurable tumor
  • Be in relatively good overall health (ECOG performance status of 0-2)

There are also several factors that would exclude a person from participating, such as having untreated brain metastases, certain active infections, or having received other cancer treatments very recently[1].

Potential Benefits

While it’s important to remember that CYC140 is still in the testing phase, researchers hope it may offer several potential benefits[1]:

  • Shrinking tumors or slowing their growth
  • Improving overall survival rates
  • Providing a new treatment option for patients who have not responded to other therapies

The study will measure these outcomes through various means, including tracking how long patients live without their disease getting worse (progression-free survival) and how long they live overall (overall survival)[1].

Safety and Side Effects

A major goal of this clinical trial is to assess the safety of CYC140. Researchers will be closely monitoring participants for any side effects or adverse reactions[1]. These will be categorized according to their type, frequency, and severity.

It’s important to note that all medications can have side effects, and since CYC140 is still in the testing phase, not all potential side effects may be known. Patients in the trial will be closely monitored and should report any unusual symptoms to their healthcare team immediately.

Aspect Details
Drug Name CYC140 Monohydrochloride Monohydrate
Drug Type Oral PLK1 inhibitor
Trial Phase Phase 1/2
Target Conditions Advanced solid tumors and lymphoma
Primary Objectives Determine safe dose, evaluate effectiveness
Key Eligibility Criteria Adults with advanced cancer, failed standard therapies
Main Endpoints Safety, tolerability, overall response rate
Administration Oral, once daily in 28-day cycles

FAQ

  • What is CYC140 Monohydrochloride Monohydrate? CYC140 Monohydrochloride Monohydrate is an oral PLK1 inhibitor being tested in clinical trials for treating advanced solid tumors and lymphoma. It's a new drug that aims to target specific cancer-related proteins.
  • What types of cancer is CYC140 being tested for? CYC140 is being tested for various advanced solid tumors and lymphoma, including metastatic colorectal cancer, cholangiocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, small cell lung cancer, and gallbladder carcinoma.
  • What are the phases of the clinical trial for CYC140? The clinical trial for CYC140 is a combined Phase 1/2 study. Phase 1 focuses on determining the safe dose and understanding how the drug works in the body. Phase 2 aims to evaluate the drug's effectiveness in treating specific types of cancer.
  • Who is eligible to participate in the CYC140 clinical trial? Eligible participants are adults (18 years or older) with confirmed advanced cancer who have either progressed on standard therapy or for whom no standard therapy exists. They must meet specific health criteria and be able to take oral medication.
  • What are the main goals of the CYC140 clinical trial? The main goals are to determine the safe dose of CYC140, understand how it works in the body, and evaluate its effectiveness in treating advanced solid tumors and lymphoma. The trial also aims to assess the drug's safety, tolerability, and impact on patients' survival and quality of life.

Ongoing Clinical Trials on Cyc140 Monohydrochloride Monohydrate

  • Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • PLK1 inhibitor: A type of drug that blocks the action of PLK1, a protein involved in cell division. By inhibiting PLK1, these drugs aim to stop cancer cells from multiplying.
  • Advanced solid tumors: Cancers that form solid masses and have spread beyond their original location or are at an advanced stage.
  • Lymphoma: A type of cancer that begins in the lymphatic system, which is part of the body's germ-fighting network.
  • Phase 1/2 clinical trial: A combined early-stage study that tests a new treatment's safety, proper dosage, and initial effectiveness in treating a specific condition.
  • Maximum-tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 dose (RP2D): The dose of a drug determined to be safe and potentially effective, which is then used in further studies.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cyc140-for-patients-with-advanced-solid-tumors-and-lymphoma/